This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.A vast majority of patients with Cystic Fibrosis (CF), a respiratory disease, also have a condition known as Exocrine pancreatic insufficiency (EPI). The main symptoms of EPI are gas, bloating, diarrhea, and loose stools, all of which are caused by poor absorption of fats, proteins, and carbohydrates. Most patients that have EPI are treated with pills containing digestive enzymes produced from pig pancreas or other sources. These enzymes have been used for over 30 years, and are thought to be effective. However, these drugs have never been fully tested, which is now required for all drugs distributed in the United States.Due to an incident a few years ago where some very high doses of pancreatic enzymes sold in Europe and the United States were found to cause intestinal problems, the U.S. Food and Drug Administration (FDA) is now requiring all enzyme producers to test the safety and efficacy of their drugs in controlled clinical studies.This research study will determine whether Eurand PEP (a pancreatic enzyme) improves fat, protein, and carbohydrate digestion. The test will be conducted using a double-blind, randomized trial, where neither the doctor, nor the patient know if the patient is using the test drug, or a placebo. The study will find out the safety and efficacy of Eurand PEP compared to that of a placebo.'

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000042-47
Application #
7603841
Study Section
Special Emphasis Panel (ZRR1-CR-8 (02))
Project Start
2007-03-01
Project End
2007-09-16
Budget Start
2007-03-01
Budget End
2007-09-16
Support Year
47
Fiscal Year
2007
Total Cost
$22,145
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419
Spengler, Erin K; Kleiner, David E; Fontana, Robert J (2017) Vemurafenib-induced granulomatous hepatitis. Hepatology 65:745-748
Heidemann, Lauren; Law, James; Fontana, Robert J (2017) A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci 62:615-625
Mehta, Rupal; Cai, Xuan; Lee, Jungwha et al. (2016) Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol 1:548-56
Heidemann, Lauren A; Navarro, Victor J; Ahmad, Jawad et al. (2016) Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci 61:2741-8
Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46

Showing the most recent 10 out of 1380 publications